ABSCI CORP Financing Cash Flow
ABSCI CORP (ABSI) reported Financing Cash Flow of $110.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- ABSCI CORP net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $102.73M.
- ABSCI CORP net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $7.56M, a 82.34% decline year-over-year.
- ABSCI CORP net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $3.84M, a 289.66% increase year-over-year.
- ABSCI CORP net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $60.32M, a 12209.59% increase year-over-year.
- ABSCI CORP net cash provided by (used in) financing activities for fiscal 2025 was $105.95M, a 28.38% increase from fiscal 2024.
- ABSCI CORP net cash provided by (used in) financing activities for fiscal 2024 was $82.53M.
- ABSCI CORP net cash provided by (used in) financing activities for fiscal 2023 was -$4.48M, a 185.60% decline from fiscal 2022.
- ABSCI CORP net cash provided by (used in) financing activities for fiscal 2022 was $5.24M, a 98.44% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $102.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $110.28M 10-Q · filed 2026-08-11 | $114.12M derived: sum of 3 quarters · filed 2026-08-11 | $174.44M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $7.56M 10-Q · filed 2026-05-07 | $11.40M derived: sum of 2 quarters · filed 2026-05-07 | $71.72M derived: sum of 3 quarters · filed 2026-05-07 | $70.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $64.16M derived: sum of 2 quarters · filed 2026-03-24 | $63.16M derived: sum of 3 quarters · filed 2026-08-11 | $105.95M 10-K · filed 2026-03-24 |
| 2025-09-30 | $60.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $59.31M derived: sum of 2 quarters · filed 2026-08-11 | $102.11M 10-Q · filed 2025-11-12 | $103.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $41.79M 10-Q · filed 2026-08-11 | $42.78M derived: sum of 3 quarters · filed 2026-08-11 | $43.27M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $42.79M 10-Q · filed 2026-05-07 | $43.78M derived: sum of 2 quarters · filed 2026-05-07 | $44.27M derived: sum of 3 quarters · filed 2026-05-07 | $44.14M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $986.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $1.48M derived: sum of 2 quarters · filed 2026-03-24 | $1.34M derived: sum of 3 quarters · filed 2026-03-24 | $82.53M 10-K · filed 2026-03-24 |
| 2024-09-30 | $490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $356.00K derived: sum of 2 quarters · filed 2025-11-12 | $81.54M 10-Q · filed 2025-11-12 | $80.31M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$134.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $81.05M 10-Q · filed 2025-08-12 | $79.81M derived: sum of 3 quarters · filed 2025-08-12 | $78.89M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $81.18M 10-Q · filed 2025-05-13 | $79.95M derived: sum of 2 quarters · filed 2025-05-13 | $79.03M derived: sum of 3 quarters · filed 2025-05-13 | $77.81M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$2.16M derived: sum of 2 quarters · filed 2025-03-18 | -$3.38M derived: sum of 3 quarters · filed 2025-03-18 | -$4.48M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$924.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.14M derived: sum of 2 quarters · filed 2024-11-12 | -$3.25M 10-Q · filed 2024-11-12 | -$1.85M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$2.32M 10-Q · filed 2024-08-14 | -$931.00K derived: sum of 3 quarters · filed 2024-08-14 | -$1.85M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$1.10M 10-Q · filed 2024-05-14 | $289.00K derived: sum of 2 quarters · filed 2024-05-14 | -$632.00K derived: sum of 3 quarters · filed 2024-05-14 | $5.19M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $472.00K derived: sum of 2 quarters · filed 2024-03-21 | $6.29M derived: sum of 3 quarters · filed 2024-03-21 | $5.24M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$921.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $4.90M derived: sum of 2 quarters · filed 2023-11-14 | $3.84M 10-Q · filed 2023-11-14 | $2.55M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $5.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $4.76M 10-Q · filed 2023-08-14 | $3.47M derived: sum of 3 quarters · filed 2023-08-14 | $211.86M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$1.06M 10-Q · filed 2023-05-15 | -$2.35M derived: sum of 2 quarters · filed 2023-05-15 | $206.03M derived: sum of 3 quarters · filed 2023-05-15 | $205.56M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $207.09M derived: sum of 2 quarters · filed 2023-03-30 | $206.62M derived: sum of 3 quarters · filed 2023-03-30 | $336.19M 10-K · filed 2023-03-30 |
| 2021-09-30 | $208.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $207.91M derived: sum of 2 quarters · filed 2022-11-09 | $337.49M 10-Q · filed 2022-11-09 | $401.88M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$474.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $129.10M 10-Q · filed 2022-08-11 | $193.49M derived: sum of 3 quarters · filed 2022-08-11 | $193.18M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $129.58M 10-Q · filed 2022-05-11 | $193.97M derived: sum of 2 quarters · filed 2022-05-11 | $193.66M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $64.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $64.08M derived: sum of 2 quarters · filed 2022-03-22 | $70.97M 10-K · filed 2022-03-22 | |
| 2020-09-30 | -$311.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $6.58M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $6.89M 10-Q · filed 2021-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |